Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Leukemia, B-Cell × Chlorambucil × Clear all

Phase

Status

Sponsor Class

INDUSTRY 2 OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 3 Lymphoma, B-Cell, Marginal Zone 2 Lymphoma, Mantle-Cell 1 Leukemia, B-Cell 1 Leukemia 1

Interventions

Cyclophosphamide 8 Rituximab 6 fludarabine 5 Bendamustine Hydrochloride 5 venetoclax 4 Lenalidomide 4 ofatumumab 3 obinutuzumab 3 ibrutinib 3 acalabrutinib 3 Vincristine 3 Immunotherapy, Adoptive 3 fludarabine phosphate 2 Bortezomib 2 Alemtuzumab 2 zanubrutinib 1 thymoglobulin 1 tenofovir alafenamide 1 ricolinostat 1 pirtobrutinib 1 pembrolizumab 1 pegaspargase 1 nelarabine 1 idelalisib 1 blinatumomab 1 Whole-Body Irradiation 1 Prednisolone 1 Pentostatin 1 Panobinostat 1 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01678430 2012-10-15

RIAltO

University of Liverpool

Phase 3 Unknown

LymphoidOther hematologic neoplasm

Leukemia, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡